Epigallocatechin gallate: A review of its beneficial properties to prevent metabolic syndrome

Nutrients

Volumn 7, Issue 7, 2015, Pages 5443-5468

  Legeay, Samuel ^a,b   Rodier, Marion ^a,b   Fillon, Laetitia ^b   Faure, Sébastien ^a,b   Clere, Nicolas ^a,b  

^a UNIVERSITÉ D'ANGERS   (France)

^b LUNAM Universite   (France)

Author keywords

Cardiovascular diseases; EGCG; Endothelial dysfunction; Epigallocatechin gallate; Green tea; Metabolic syndrome

Indexed keywords

EPIGALLOCATECHIN GALLATE; CATECHIN; TEA;

CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; REVIEW; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; CHEMISTRY; TEA;

BIOLOGICAL AVAILABILITY; CATECHIN; HUMANS; METABOLIC SYNDROME X; TEA;

EID: 84936966844     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7075230     Document Type: Review

References (151)

1. Kassi, E.; Pervanidou, P.; Kaltsas, G.; Chrousos, G. Metabolic syndrome: Definitions and controversies. BMC Med. 2011, 9, 48. [CrossRef]
2. Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.; Loria, C.M., Smith, S.C., et al. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009, 120, 1640-1645.
3. Van Rooy, M.J.; Pretorius, E. Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke. Thromb. Res. 2015, 135, 434-442. [CrossRef]
4. Keske, M.A.; Ng, H.L.; Premilovac, D.; Rattigan, S.; Kim, J.A.; Munir, K.; Yang, P.; Quon, M.J. Vascular and metabolic actions of the green tea polyphenol epigallocatechin gallate. Curr. Med. Chem. 2015, 22, 59-69. [CrossRef]
5. Pandey, K.B.; Rizvi, S.I. Plant polyphenols as dietary antioxidants in human health and disease. Oxid. Med. Cell. Longev. 2009, 2, 270-278. [CrossRef]
6. Warnakulasuriya, S.N., Ziaullah, Rupasinghe H.P. Long chain fatty acid acylated derivatives of quercetin-3-O-glucoside as antioxidants to prevent lipid oxidation. Biomolecules 2014, 4, 980-993. [CrossRef]
7. Wu, C.M.; Lin, K.W.; Teng, C.H.; Huang, A.M.; Chen, Y.C.; Yen, M.H.; Wu, W.B.; Pu, Y.S.; Lin, C.N. Chalcone derivatives inhibit human platelet aggregation and inhibit growth in human bladder cancer cells. Biol. Pharm. Bull. 2014, 37, 1191-1198. [CrossRef]
8. Ahmad, A.; Khan, R.M.; Alkharfy, K.M. Effects of selected bioactive natural products on the vascular endothelium. J. Cardiovasc. Pharmacol. 2013, 62, 111-121. [CrossRef]
9. Wang, X.; Ouyang, Y.Y.; Liu, J.; Zhao, G. Flavonoid intake and risk of CVD: A systematic review and meta-analysis of prospective cohort studies. Br. J. Nutr. 2014, 111, 1-11. [CrossRef]
10. Graham, H.N. Green tea composition, consumption, and polyphenol chemistry. Prev. Med. 1992, 21, 334-350. [CrossRef]
11. McKay, D.L.; Blumberg, J.B. The role of tea in human health: An update. J. Am. Coll. Nutr. 2002, 21, 1-13. [CrossRef]
12. Cabrera, C.; Giménez, R.; López, M.C. Determination of tea components with antioxidant activity. J. Agric. Food Chem. 2003, 51, 4427-4435. [CrossRef]
13. Cabrera, C.; Artacho, R.; Giménez, R. Beneficial effects of green tea—A review. J. Am. Coll. Nutr. 2006, 25, 79-99. [CrossRef]
14. Komes, D.; Belscak-Cvitanovic, A.; Horzic, D.; Rusak, G.; Likic, S.; Berendika, M. Phenolic composition and antioxidant properties of some traditionally used medicinal plants affected by the extraction time and hydrolysis. Phytochem. Anal. 2011, 22, 172-180. [CrossRef]
15. Del Rio, D.; Stewart, A.J.; Mullen, W.; Burns, J.; Lean, M.E.; Brighenti, F.; Crozier, A. HPLC-MSn analysis of phenolic compounds and purine alkaloids in green and black tea. J. Agric. Food Chem. 2004, 52, 2807-2815. [CrossRef]
16. Higdon, J.V.; Frei, B. Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Crit. Rev. Food Sci. Nutr. 2003, 43, 89-143. [CrossRef]
17. Rice-Evans, C. Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans. Proc. Soc. Exp. Biol. Med. 1999, 220, 262-266. [CrossRef]
18. Rice-Evans, C.; Leake, D.; Bruckdorfer, K.R.; Diplock, A.T. Practical approaches to low density lipoprotein oxidation: Whys, wherefores and pitfalls. Free Radic. Res. 1996, 25, 285-311. [CrossRef]
19. Jomova, K.; Valko, M. Advances in metal-induced oxidative stress and human disease. Toxicology 2011, 283, 65-87. [CrossRef]
20. Mandel, S.A.; Amit, T.; Kalfon, L.; Reznichenko, L.; Weinreb, O.; Youdim, M.B. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: Special reference to epigallocatechin gallate (EGCG). J. Alzheimers Dis. 2008, 15, 211-222.
21. Hyung, S.J.; DeToma, A.S.; Brender, J.R.; Lee, S.; Vivekanandan, S.; Kochi, A.; Choi, J.S.; Ramamoorthy, A.; Ruotolo, B.T.; Lim, M.H. Insights into antiamyloidogenic properties of the green tea extract (—)-epigallocatechin-3-gallate toward metal-associated amyloid-β species. Proc. Natl. Acad. Sci. USA 2013, 110, 3743-3748. [CrossRef]
22. Pirker, K.F.; Baratto, M.C.; Basosi, R.; Goodman, B.A. Influence of pH on the speciation of copper(II) in reactions with the green tea polyphenols, epigallocatechin gallate and gallic acid. J. Inorg. Biochem. 2012, 112, 10-16. [CrossRef]
23. Wu, F.; Sun, H.; Kluz, T.; Clancy, H.A.; Kiok, K.; Costa, M. Epigallocatechin-3-gallate (EGCG) protects against chromate-induced toxicity in vitro. Toxicol. Appl. Pharmacol. 2012, 258, 166-175. [CrossRef]
24. Abib, R.T.; Peres, K.C.; Barbosa, A.M.; Peres, T.V.; Bernardes, A.; Zimmermann, L.M.; Quincozes-Santos, A.; Fiedler, H.D.; Leal, R.B., Farina, M., et al. Epigallocatechin-3-gallate protects rat brain mitochondria against cadmium-induced damage. Food Chem. Toxicol. 2011, 49, 2618-2623. [CrossRef]
25. 2+ in HL-7702 cells. Toxicol. Mech. Methods 2014, 24, 259-267. [CrossRef]
26. Morel, I.; Lescoat, G.; Cillard, P.; Cillard, J. Role of flavonoids and iron chelation in antioxidant action. Methods Enzymol. 1994, 234, 437-443.
27. Nakagawa, H.; Hasumi, K.; Woo, J.T.; Nagai, K.; Wachi, M. Generation of hydrogen peroxide primarily contributes to the induction of Fe(II)-dependent apoptosis in jurkat cells by (—)-epigallocatechin gallate. Carcinogenesis 2004, 25, 1567-1574. [CrossRef]
28. Azam, S.; Hadi, N.; Khan, N.U.; Hadi, S.M. Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3-gallate: Implications for anticancer properties. Toxicol. In Vitro 2004, 18, 555-561. [CrossRef]
29. Miura, Y.H.; Tomita, I.; Watanabe, T.; Hirayama, T.; Fukui, S. Active oxygens generation by flavonoids. Biol. Pharm. Bull. 1998, 21, 93-96. [CrossRef]
30. Hou, Z.; Sang, S.; You, H.; Lee, M.J.; Hong, J.; Chin, K.V.; Yang, C.S. Mechanism of action of (—)-epigallocatechin-3-gallate: Auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res. 2005, 65, 8049-8056.
31. Sang, S.; Lee, M.J.; Hou, Z.; Ho, C.T.; Yang, C.S. Stability of tea polyphenol (—)-epigallocatechin-3-gallate and formation of dimers and epimers under common experimental conditions. J. Agric. Food Chem. 2005, 53, 9478-9484. [CrossRef]
32. Ran, Z.H.; Chen, C.; Xiao, S.D. Epigallocatechin-3-gallate ameliorates rats colitis induced by acetic acid. Biomed. Pharmacother. 2008, 3, 189-196. [CrossRef]
33. Meng, Q.; Velalar, C.N.; Ruan, R. Effects of epigallocatechin-3-gallate on mitochondrial integrity and antioxidative enzyme activity in the aging process of human fibroblast. Free Radic. Biol. Med. 2008, 44, 1032-1041. [CrossRef]
34. 34.Brückner, M.; Westphal, S.; Domschke, W.; Kucharzik, T.; Lügering, A. Green tea polyphenol epigallocatechin-3-gallate shows therapeutic antioxidative effects in a murine model of colitis. J. Crohns Colitis 2008, 2, 226-235. [CrossRef]
35. Min, N.Y.; Kim, J.H.; Choi, J.H.; Liang, W.; Ko, Y.J.; Rhee, S.; Bang, H.; Ham, S.W.; Park, A.J.; Lee, K.H. Selective death of cancer cells by preferential induction of reactive oxygen species in response to (—)-epigallocatechin-3-gallate. Biochem. Biophys. Res. Commun. 2012, 421, 91-97. [CrossRef]
36. Mazzanti, G.; Menniti-Ippolito, F.; Moro, P.A.; Cassetti, F.; Raschetti, R.; Santuccio, C.; Mastrangelo, S. Hepatotoxicity from green tea: A review of the literature and two unpublished cases. Eur. J. Clin. Pharmacol. 2009, 65, 331-341. [CrossRef]
37. Lambert, J.D.; Elias, R.J. The antioxidant and pro-oxidant activities of green tea polyphenols: A role in cancer prevention. Arch. Biochem. Biophys. 2010, 501, 65-72. [CrossRef]
38. Li, G.X.; Chen, Y.K.; Hou, Z.; Xiao, H.; Jin, H.; Lu, G.; Lee, M.J.; Liu, B.; Guan, F., Yang, Z., et al. Pro-oxidative activities and dose-response relationship of (—)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: A comparative study in vivo and in vitro. Carcinogenesis 2010, 31, 902-910. [CrossRef]
39. Lee, M.J.; Maliakal, P.; Chen, L.; Meng, X.; Bondoc, F.Y.; Prabhu, S.; Lambert, G.; Mohr, S.; Yang, C.S. Pharmacokinetics of tea catechins after ingestion of green tea and (—)-epigallocatechin-3-gallate by humans: Formation of different metabolites and individual variability. Cancer Epidemiol. Biomarkers Prev. 2002, 11, 1025-1032.
40. Williamson, G.; Dionisi, F.; Renouf, M. Flavanols from green tea and phenolic acids from coffee: Critical quantitative evaluation of the pharmacokinetic data in humans after consumption of single doses of beverages. Mol. Nutr. Food Res. 2011, 55, 864-873. [CrossRef]
41. Miller, R.J.; Jackson, K.G.; Dadd, T.; Mayes, A.E.; Brown, A.L.; Lovegrove, J.A.; Minihane, A.M. The impact of the catechol-O-methyltransferase genotype on vascular function and blood pressure after acute green tea ingestion. Mol. Nutr. Food Res. 2012, 56, 966-975. [CrossRef]
42. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Rémésy, C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 2005, 81, 230S-242S.
43. Moore, R.J.; Jackson, K.G.; Minihane, A.M. Green tea (Camellia sinensis) catechins and vascular function. Br. J. Nutr. 2009, 102, 1790-1802. [CrossRef]
44. Ullmann, U.; Haller, J.; Decourt, J.P.; Girault, N.; Girault, J.; Richard-Caudron, A.S.; Pineau, B.; Weber, P. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J. Int. Med. Res. 2003, 31, 88-101. [CrossRef]
45. Chen, L.; Lee, M.J.; Li, H.; Yang, C.S. Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab. Dispos. 1997, 25, 1045-1050.
46. Chu, K.O.; Wang, C.C.; Chu, C.Y.; Chan, K.P.; Rogers, M.S.; Choy, K.W.; Pang, C.P. Pharmacokinetic studies of green tea catechins in maternal plasma and fetuses in rats. J. Pharm. Sci. 2006, 95, 1372-1381. [CrossRef]
47. Lin, L.C.; Wang, M.N.; Tseng, T.Y.; Sung, J.S.; Tsai, T.H. Pharmacokinetics of (—)-epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution. J. Agric. Food Chem. 2007, 55, 1517-1524. [CrossRef]
48. Scholey, A.; Downey, L.A.; Ciorciari, J.; Pipingas, A.; Nolidin, K.; Finn, M.; Wines, M.; Catchlove, S.; Terrens, A., Barlow, E., et al. Acute neurocognitive effects of epigallocatechin gallate (EGCG). Appetite 2012, 58, 767-770. [CrossRef]
49. Meng, X.; Sang, S.; Zhu, N.; Lu, H.; Sheng, S.; Lee, M.J.; Ho, C.T.; Yang, C.S. Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats. Chem. Res. Toxicol. 2002, 15, 1042-1050. [CrossRef]
50. Schantz, M.; Erk, T.; Richling, E. Metabolism of green tea catechins by the human small intestine. Biotechnol. J. 2010, 5, 1050-1059. [CrossRef]
51. Van’t Slot, G.; Humpf, H.U. Degradation and metabolism of catechin, epigallocatechin-3-gallate (EGCG), and related compounds by the intestinal microbiota in the pig cecum model. J. Agric. Food Chem. 2009, 57, 8041-8048. [CrossRef]
52. Lee, M.J.; Wang, Z.Y.; Li, H.; Chen, L.; Sun, Y.; Gobbo, S.; Balentine, D.A.; Yang, C.S. Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol. Biomarkers Prev. 1995, 4, 393-399.
53. Natsume, M.; Osakabe, N.; Yasuda, A.; Osawa, T.; Terao, J. Inhibitory effects of conjugated epicatechin metabolites on peroxynitrite-mediated nitrotyrosine formation. J. Clin. Biochem. Nutr. 2008, 42, 50-53. [CrossRef]
54. Basu-Modak, S.; Gordon, M.J.; Dobson, L.H.; Spencer, J.P.; Rice-Evans, C.; Tyrrell, R.M. Epicatechin and its methylated metabolite attenuate UVA-induced oxidative damage to human skin fibroblasts. Free Radic. Biol. Med. 2003, 35, 910-921. [CrossRef]
55. Steffen, Y.; Gruber, C.; Schewe, T.; Sies, H. Mono-O-methylated flavanols and other flavonoids as inhibitors of endothelial NADPH oxidase. Arch. Biochem. Biophys. 2008, 469, 209-219. [CrossRef]
56. Yiannakopoulou, E.Ch. Effect of green tea catechins on breast carcinogenesis: A systematic review of in vitro and in vivo experimental studies. Eur. J. Cancer Prev. 2014, 23, 84-89. [CrossRef]
57. Mereles, D.; Hunstein, W. Epigallocatechin-3-gallate (EGCG) for clinical trials: More pitfalls than promises? Int. J. Mol. Sci. 2011, 12, 5592-5603. [CrossRef]
58. Visioli, F.; Davalos, A. Polyphenols and cardiovascular disease: A critical summary of the evidence. Mini Rev. Med. Chem. 2011, 11, 1186-1190.
59. Babu, S.; Uppu, S.; Claville, M.O.; Uppu, R.M. Prooxidant actions of bisphenol A (BPA) phenoxyl radicals: Implications to BPA-related oxidative stress and toxicity. Toxicol. Mech. Methods 2013, 23, 273-280. [CrossRef]
60. Halberg, N.; Wernstedt-Asterholm, I.; Scherer, P.E. The adipocyte as an endocrine cell. Endocrinol. Metab. Clin. N. Am. 2008, 37, 753-768. [CrossRef]
61. Lau, D.C.; Dhillon, B.; Yan, H.; Szmitko, P.E.; Verma, S. Adipokines: Molecular links between obesity and atheroslcerosis. Am. J. Physiol. Heart Circ. Physiol. 2005, 288, 2031-2041. [CrossRef]
62. Ouchi, N.; Parker, J.L.; Lugus, J.J.; Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11, 85-97. [CrossRef]
63. Mendonca, F.M.; de Sousa, F.R.; Barbosa, A.L.; Martins, S.C.; Araujo, R.L.; Soares, R.; Abreu, C. Metabolic syndrome and risk of cancer: Which link? Metabolism 2015, 64, 182-189. [CrossRef]
64. Cohen, D.H.; LeRoith, D. Obesity, type 2 diabetes, and cancer: The insulin and IGF connection. Endocr. Relat. Cancer 2012, 19, 27-45. [CrossRef]
65. Maury, E.; Brichard, S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol. Cell. Endocrinol. 2010, 314, 1-16. [CrossRef]
66. Maffei, M.; Halaas, J.; Ravussin, E.; Pratley, R.E.; Lee, G.H.; Zhang, Y.; Fei, H.; Kim, S.; Lallone, R., Ranganathan, S., et al. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat. Med. 1995, 1, 1155-1161. [CrossRef]
67. Hutley, L.; Prins, J.B. Fat as an endocrine organ: Relationship to the metabolic syndrome. Am. J. Med. Sci. 2005, 330, 280-289. [CrossRef]
68. DePaoli, A.M. 20 years of leptin: Leptin in common obesity and associated disorders of metabolism. J. Endocrinol. 2014, 223, 71-81. [CrossRef]
69. Shirasaka, T.; Takasaki, M.; Kannan, H. Cardiovascular effects of leptin and orexins. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 284, 639-651. [CrossRef]
70. Momin, A.U.; Melikian, N.; Shah, A.M.; Grieve, D.J.; Wheatcroft, S.B.; John, L.; El Gamel, A.; Desai, J.B.; Nelson, T., Driver, C., et al. Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: Evidence for tissue specificity of leptin resistance. Eur. Heart J. 2006, 27, 2294-2299. [CrossRef]
71. Adya, R.; Tan, B.K.; Randeva, H.S. Differential effects of leptin and adiponectin in endothelial angiogenesis. J. Diabetes Res. 2015, 2015, 648239
72. Naseem, K.M. The role of nitric oxide in cardiovascular diseases. Mol. Aspects Med. 2005, 26, 33-65. [CrossRef]
73. Yamagishi, S.I.; Edelstein, D.; Du, X.L.; Kaneda, Y.; Guzman, M.; Brownlee, M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J. Biol. Chem. 2001, 276, 25096-25100. [CrossRef]
74. Cooper, D.; Stokes, K.Y.; Tailor, A.; Granger, D.N. Oxidative stress promotes blood cell-endothelial cell interactions in the microcirculation. Cardiovasc. Toxicol. 2002, 2, 165-180. [CrossRef]
75. Snoussi, C.; Ducroc, R.; Hamdaoui, M.H.; Dhaouadi, K.; Abaidi, H.; Cluzeaud, F.; Nazaret, C.; Le Gall, M.; Bado, A. Green tea decoction improves glucose tolerance and reduces weight gain of rats fed normal and high-fat diet. J. Nutr. Biochem. 2014, 25, 557-564. [CrossRef]
76. Fiorini, R.N.; Donovan, J.L.; Rodwell, D.; Evans, Z.; Cheng, G.; May, H.D.; Milliken, C.E.; Markowitz, J.S.; Campbell, C., Haines, J.K., et al. Short-term administration of (—)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/reperfusion injury in steatotic mice. Liver Transpl. 2005, 11, 298-308. [CrossRef]
77. Friedrich, M.; Petzke, K.J.; Raederstorff, D.; Wolfram, S.; Klaus, S. Acute effects of epigallocatechin gallate from green tea on oxidation and tissue incorporation of dietary lipids in mice fed a high-fat diet. Int. J. Obes. 2012, 36, 735-743. [CrossRef]
78. Grove, K.A.; Sae-tan, S.; Kennett, M.J.; Lambert, J.D. (—)-Epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice. Obesity 2012, 20, 2311-2313. [CrossRef]
79. Wang, S.; Sun, Z.; Dong, S.; Liu, Y. Molecular interactions between (—)-epigallocatechin gallate analogs and pancreatic lipase. PLoS ONE 2014, 9, e111143. [CrossRef]
80. Ikeda, I.; Tsuda, K.; Suzuki, Y.; Kobayashi, M.; Unno, T.; Tomoyori, H.; Goto, H.; Kawata, Y.; Imaizumi, K., Nozawa, A., et al. Tea catechins with a galloyl moiety suppress postprandial hypertriacylglycerolemia by delaying lymphatic transport of dietary fat in rats. J. Nutr. 2005, 135, 155-159.
81. Shishikura, Y.; Khokhar, S.; Murray, B.S. Effects of tea polyphenols on emulsification of olive oil in a small intestine model system. J. Agric. Food Chem. 2006, 54, 1906-1913. [CrossRef]
82. Huang, J.B.; Zhang, Y.; Zhou, Y.B.; Wan, X.C.; Zhang, J.S. Effects of epigallocatechin gallate on lipid metabolism and its underlying molecular mechanism in broiler chickens. J. Anim. Physiol. Anim. Nutr. 2014. [CrossRef]
83. Sae-Tan, S.; Grove, K.A.; Kennett, M.J.; Lambert, J.D. (—)-Epigallocatechin-3-gallate increases the expression of genes related to fat oxidation in the skeletal muscle of high fat-fed mice. Food Funct. 2011, 2, 111-116. [CrossRef]
84. Nakagawa, S.; Kojima, Y.; Sekino, K.; Yamato, S. Effect of polyphenols on 3-hydroxy-3-methylglutaryl-coenzyme a lyase activity in human hepatoma Hep G2 cell extracts. Biol. Pharm. Bull. 2013, 36, 1902-1906. [CrossRef]
85. Kaur, J. A comprehensive review on metabolic syndrome. Cardiol. Res. Pract. 2014. [CrossRef]
86. Petersen, K.F.; Shulman, G.I. Etiology of insulin resistance. Am. J. Med. 2006, 119, 10-16. [CrossRef]
87. Muniyappa, R.; Montagnani, M.; Koh, K.K.; Quon, M.J. Cardiovascular actions of insulin. Endocr. Rev. 2007, 28, 463-491. [CrossRef]
88. Muniyappa, R.; Yavuz, S. Metabolic actions of angiotensin II and insulin: A microvascular endothelial balancing act. Mol. Cell. Endocrinol. 2013, 378, 59-69. [CrossRef]
89. Ortsater, H.; Grankvist, N.; Wolfram, S.; Kuehn, N.; Sjoholm, A. Diet supplementation with green tea extract epigallocatechin gallate prevents progression to glucose intolerance in db/db mice. Nutr. Metab. 2012, 9, 11. [CrossRef]
90. Fu, Z.; Zhen, W.; Yuskavage, J.; Liu, D. Epigallocatechin gallate delays the onset of type 1 diabetes in spontaneous non-obese diabetic mice. Br. J. Nutr. 2011, 105, 1218-1225. [CrossRef]
91. Zhang, Z.; Ding, Y.; Dai, X.; Wang, J.; Li, Y. Epigallocatechin-3-gallate protects pro-inflammatory cytokine induced injuries in insulin-producing cells through the mitochondrial pathway. Eur. J. Pharmacol. 2011, 670, 311-316. [CrossRef]
92. Silva, K.C.; Rosales, M.A.; Hamassaki, D.E.; Saito, K.C.; Faria, A.M.; Ribeiro, P.A.; Faria, J.B.; Faria, J.M. Green tea is neuroprotective in diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2013, 54, 1325-1336. [CrossRef]
93. Yamabe, N.; Yokozawa, T.; Oya, T.; Kim, M. Therapeutic potential of (—)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J. Pharmacol. Exp. Ther. 2006, 319, 228-236. [CrossRef]
94. Raposo, D.; Morgado, C.; Pereira-Terra, P.; Tavares, I. Nociceptive spinal cord neurons of laminae I-III exhibit oxidative stress damage during diabetic neuropathy which is prevented by early antioxidant treatment with epigallocatechin-gallate (EGCG). Brain Res. Bull. 2015, 110, 68-75. [CrossRef]
95. Nicholas, S.B.; Liu, J.; Kim, J.; Ren, Y.; Collins, A.R.; Nguyen, L.; Hsueh, W.A. Critical role for osteopontin in diabetic nephropathy. Kidney Int. 2010, 77, 588-600. [CrossRef]
96. Junaid, A.; Amara, F.M. Osteopontin: Correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells. Histopathology 2004, 44, 136-146. [CrossRef]
97. Yoon, S.P.; Maeng, Y.H.; Hong, R.; Lee, B.R.; Kim, C.G.; Kim, H.L.; Chung, J.H.; Shin, B.C. Protective effects of epigallocatechin gallate (EGCG) on streptozotocin-induced diabetic nephropathy in mice. Acta Histochem. 2014, 116, 1210-1215. [CrossRef]
98. Yan, J.; Feng, Z.; Liu, J.; Shen, W.; Wang, Y.; Wertz, K.; Weber, P.; Long, J. Enhanced autophagy plays a cardinal role in mitochondrial dysfunction in type 2 diabetic Goto-Kakizaki (GK) rats: Ameliorating effects of (—)-epigallocatechin-3-gallate. J. Nutr. Biochem. 2012, 23, 716-724. [CrossRef]
99. Kim, J.J.; Tan, Y.; Xiao, L.; Sun, Y.L.; Qu, X. Green tea polyphenol epigallocatechin-3-gallate enhance glycogen synthesis and inhibit lipogenesis in hepatocytes. Biomed. Res. Int. 2013. [CrossRef]
100. Cordero-Herrera, I.; Martin, M.A.; Goya, L.; Ramos, S. Cocoa flavonoids attenuate high glucose-induced insulin signalling blockade and modulate glucose uptake and production in human Hep G2 cells. Food Chem. Toxicol. 2014, 64, 10-19. [CrossRef]
101. Reynolds, C.M.; McGillicuddy, F.C.; Harford, K.A.; Finucane, O.M.; Mills, K.H.; Roche, H.M. Dietary saturated fatty acids prime the NLRP3 inflammasome via TLR4 in dendritic cells-implications for diet-induced insulin resistance. Mol. Nutr. Food Res. 2012, 56, 1212-1222. [CrossRef]
102. Pal, D.; Dasgupta, S.; Kundu, R.; Maitra, S.; Das, G.; Mukhopadhyay, S.; Ray, S.; Majumdar, S.S.; Bhattacharya, S. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. 2012, 18, 1279-1285. [CrossRef]
103. Bao, S.; Cao, Y.; Fan, C.; Fan, Y.; Bai, S.; Teng, W.; Shan, Z. Epigallocatechin gallate improves insulin signaling by decreasing toll-like receptor 4 (TLR4) activity in adipose tissues of high-fat diet rats. Mol. Nutr. Food Res. 2014, 58, 677-686. [CrossRef]
104. Eckel, R.H.; Alberti, K.G.; Grundy, S.M.; Zimmet, P.Z. The metabolic syndrome. Lancet 2010, 375, 181-183. [CrossRef]
105. Taghibiglou, C.; Rashid-Kolvear, F.; van Iderstine, S.C.; Le-Tien, H.; Fantus, I.G.; Lewis, G.F.; Adeli, K. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J. Biol. Chem. 2002, 277, 793-803. [CrossRef]
106. Leonard, A.; Tun, T.K.; Gaffney, R.; Sharma, J.; Gibney, J.; Boran, G. Factors influencing elevated serum apolipoprotein B48 in diabetic and control participants. Br. J. Biomed. Sci. 2014, 71, 145-150.
107. Lee, C.C.; Lorenzo, C.; Haffner, S.M.; Wagenknecht, L.E.; Goodarzi, M.O.; Stefanovski, D.; Norris, J.M.; Rewers, M.J.; Hanley, A.J. Components of metabolic syndrome and 5-year change in insulin clearance—The insulin resistance atherosclerosis study. Diabetes Obes. Metab. 2013, 15, 441-447. [CrossRef]
108. 108. Katsiki, N.; Nikolic, D.; Montalto, G.; Banach, M.; Mikhailidis, D.P.; Rizzo, M. The role of fibrate treatment in dyslipidemia: An overview. Curr. Pharm. Des. 2013, 19, 3124-3131. [CrossRef]
109. Goto, T.; Saito, Y.; Morikawa, K.; Kanamaru, Y.; Nagaoka, S. Epigallocatechin gallate changes mRNA expression level of genes involved in cholesterol metabolism in hepatocytes. Br. J. Nutr. 2012, 107, 769-773. [CrossRef]
110. Moreno, M.F.; de Laquila, R.; Okuda, M.H.; Lira, F.S.; de Souza, G.I.; de Souza, C.T.; Telles, M.M.; Ribeiro, E.B.; do Nascimento, C.M.; Oyama, L.M. Metabolic profile response to administration of epigallocatechin-3-gallate in high-fat-fed mice. Diabetol. Metab. Syndr. 2014, 6, 84. [CrossRef]
111. Ahmad, R.S.; Butt, M.S.; Sultan, M.T.; Mushtaq, Z.; Ahmad, S.; Dewanjee, S.; de Feo, V.; Zia-Ul-Haq, M. Preventive role of green tea catechins from obesity and related disorders especially hypercholesterolemia and hyperglycemia. J. Transl. Med. 2015, 13, 79. [CrossRef]
112. Luo, M.; Kannar, K.; Wahlqvist, M.L.; O’Brien, R.C. Inhibition of LDL oxidation by green tea extract. Lancet 1997, 349, 360-361. [CrossRef]
113. Yang, T.T.; Koo, M.W. Inhibitory effect of chinese green tea on endothelial cell-induced LDL oxidation. Atherosclerosis 2000, 148, 67-73. [CrossRef]
114. Ferrannini, E.; Natali, A. Essential hypertension, metabolic disorders, and insulin resistance. Am. Heart J. 1991, 121, 1274-1282. [CrossRef]
115. Fogari, R.; Zoppi, A.; Ferrari, I.; Mugellini, A.; Preti, P.; Derosa, G. Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome. Clin. Exp. Hypertens. 2010, 32, 245-250. [CrossRef]
116. Malhotra, A.; Kang, B.P.; Cheung, S.; Opawumi, D.; Meggs, L.G. Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I. Diabetes 2001, 50, 1918-1926. [CrossRef]
117. Mahmood, I.H.; Abed, M.N.; Merkhan, M.M. Effects of blocking of angiotensin system on the prevalence of metabolic syndrome in type 2 diabetic patients. Pak. J. Med. Sci. 2013, 29, 140-143.
118. Goodfriend, T.L.; Calhoun, D.A. Resistant hypertension, obesity, sleep apnea, and aldosterone: Theory and therapy. Hypertension 2004, 43, 518-524. [CrossRef]
119. Endemann, D.H.; Schiffrin, E.L. Endothelial dysfunction. J. Am. Soc. Nephrol. 2004, 15, 1983-1992. [CrossRef]
120. Kraemer-Aguiar, L.G.; Laflor, C.M.; Bouskela, E. Skin microcirculatory dysfunction is already present in normoglycemic subjects with metabolic syndrome. Metabolism 2008, 57, 1740-1746. [CrossRef]
121. Koppenol, W.H.; Moreno, J.J.; Pryor, W.A.; Ischiropoulos, H.; Beckman, J.S. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem. Res. Toxicol. 1992, 5, 834-842. [CrossRef]
122. Madamanchi, N.R.; Moon, S.K.; Hakim, Z.S.; Clark, S.; Mehrizi, A.; Patterson, C.; Runge, M.S. Differential activation of mitogenic signaling pathways in aortic smooth muscle cells deficient in superoxide dismutase isoforms. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 950-956. [CrossRef]
123. Shrivastava, A.K.; Singh, H.V.; Raizada, A.; Singh, S.K.; Pandey, A.; Singh, N.; Yadav, D.S.; Sharma, H. Inflammatory markers in patients with rheumatoid arthritis. Allergol. Immunopathol. 2015, 43, 81-87. [CrossRef]
124. Zhang, T.; Yang, D.; Fan, Y.; Xie, P.; Li, H. Epigallocatechin-3-gallate enhances ischemia/reperfusion-induced apoptosis in human umbilical vein endothelial cells via AKT and MAPK pathways. Apoptosis 2009, 14, 1245-1254. [CrossRef]
125. Prigent-Tessier, A.; Quirie, A.; Maguin-Gate, K.; Szostak, J.; Mossiat, C.; Nappey, M.; Devaux, S.; Marie, C.; Demougeot, C. Physical training and hypertension have opposite effects on endothelial brain-derived neurotrophic factor expression. Cardiovasc. Res. 2013, 100, 374-382. [CrossRef]
126. Avogaro, A.; de Kreutzenberg, S.V.; Fadini, G. Endothelial dysfunction: Causes and consequences in patients with diabetes mellitus. Diabetes Res. Clin. Pract. 2008, 82, S94-S101. [CrossRef]
127. Mudau, M.; Genis, A.; Lochner, A.; Strijdom, H. Endothelial dysfunction: The early predictor of atherosclerosis. Cardiovasc. J. Afr. 2012, 23, 222-231. [CrossRef]
128. Tang, E.H.; Vanhoutte, P.M. Endothelial dysfunction: A strategic target in the treatment of hypertension? Pflugers Arch. 2010, 459, 995-1004. [CrossRef]
129. Jiang, D.J.; Jiang, J.L.; Tan, G.S.; Huang, Z.Z.; Deng, H.W.; Li, Y.J. Demethylbellidifolin inhibits adhesion of monocytes to endothelial cells via reduction of tumor necrosis factor alpha and endogenous nitric oxide synthase inhibitor level. Planta Med. 2003, 69, 1150-1152.
130. Böger, R.H.; Sydow, K.; Borlak, J.; Thum, T.; Lenzen, H.; Schubert, B.; Tsikas, D.; Bode-Böger, S.M. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethionine-dependent methyltransferases. Circ. Res. 2000, 87, 99-105. [CrossRef]
131. G-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J. Biochem. 1995, 117, 237-238. [CrossRef]
132. Xuan, C.; Tian, Q.W.; Li, H.; Zhang, B.B.; He, G.W.; Lun, L.M. Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: A meta-analysis based on 4713 participants. Eur. J. Prev. Cardiol. 2015. [CrossRef]
133. Tang, W.J.; Hu, C.P.; Chen, M.F.; Deng, P.Y.; Li, Y.J. Epigallocatechin gallate preserves endothelial function by reducing the endogenous nitric oxide synthase inhibitor level. Can. J. Physiol. Pharmacol. 2006, 84, 163-171. [CrossRef]
134. ʺ, is essential for the PI3-kinase/Akt-dependent phosphorylation of endothelial NO synthase in endothelial cells and relaxation of coronary artery rings. Food Funct. 2013, 4, 249-257. [CrossRef]
135. Hall, J.E.; Henegar, J.R.; Dwyer, T.M.; Liu, J.; Da Silva, A.A.; Kuo, J.J.; Tallam, L. Is obesity a major cause of chronic kidney disease? Adv. Ren. Replace. Ther. 2004, 11, 41-54. [CrossRef]
136. Briones, A.M.; Nguyen Dinh Cat, A.; Callera, G.E.; Yogi, A.; Burger, D.; He, Y.; Correa, J.W.; Gagnon, A.M.; Gomez-Sanchez, C.E., Gomez-Sanchez, E.P., et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: Implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012, 59, 1069-1078. [CrossRef]
137. Ondetti, M.A.; Cushman, D.W. Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. J. Med. Chem. 1981, 24, 355-361. [CrossRef]
138. Li, F.; Takahashi, Y.; Yamaki, K. Inhibitory effect of catechin-related compounds on renin activity. Biomed. Res. 2013, 34, 167-171. [CrossRef]
139. Potenza, M.A.; Marasciulo, F.L.; Tarquinio, M.; Tiravanti, E.; Colantuono, G.; Federici, A.; Kim, J.A.; Quon, M.J.; Montagnani, M., EGCG a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am. J. Physiol. Endocrinol. Metab. 2007, 292, 1378-1387. [CrossRef]
140. Kiskinis, E.; Hallberg, M.; Christian, M.; Olofsson, M.; Dilworth, S.M.; White, R.; Parker, M.G. RIP140 directs histone and DNA methylation to silence Ucp1 expression in white adipocytes. EMBO J. 2007, 26, 4831-4840. [CrossRef]
141. Montague, C.T.; Farooqi, I.S.; Whitehead, J.P.; Soos, M.A.; Rau, H.; Wareham, N.J.; Sewter, C.P.; Digby, J.E.; Mohammed, S.N., Hurst, J.A., et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997, 387, 903-908.
142. Lee, H.A.; Lee, D.Y.; Lee, H.J.; Han, H.S.; Kim, I. Enrichment of (pro)renin receptor promoter with activating histone codes in the kidneys of spontaneously hypertensive rats. J. Renin Angiotensin Aldosterone Syst. 2012, 13, 11-18. [CrossRef]
143. Jiang, Q.; Yuan, H.; Xing, X.; Liu, J.; Huang, Z.; Du, X. Methylation of adrenergic β1 receptor is a potential epigenetic mechanism controlling antihypertensive response to metoprolol. Indian J. Biochem. Biophys. 2011, 48, 301-307.
144. Boqué, N.; de la Iglesia, R.; de la Garza, A.L.; Milagro, F.I.; Olivares, M.; Banuelos, O.; Soria, A.C.; Rodriguez-Sanchez, S.; Martinez, J.A.; Campion, J. Prevention of diet-induced obesity by apple polyphenols in wistar rats through regulation of adipocyte gene expression and DNA methylation patterns. Mol. Nutr. Food Res. 2013, 57, 1473-1478. [CrossRef]
145. Gerhauser, C. Epigenetic impact of dietary isothiocyanates in cancer chemoprevention. Curr. Opin. Clin. Nutr. Metab. Care 2013, 16, 405-410. [CrossRef]
146. Chen, I.J.; Liu, C.Y.; Chiu, J.P.; Hsu, C.H. Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial. Clin. Nutr. 2015. [CrossRef]
147. Bogdanski, P.; Suliburska, J.; Szulinska, M.; Stepien, M.; Pupek-Musialik, D.; Jablecka, A. Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients. Nutr. Res. 2012, 32, 421-427. [CrossRef]
148. Suliburska, J.; Bogdanski, P.; Szulinska, M.; Stepien, M.; Pupek-Musialik, D.; Jablecka, A. Effects of green tea supplementation on elements, total antioxidants, lipids, and glucose values in the serum of obese patients. Biol. Trace Elem. Res. 2012, 149, 315-322. [CrossRef]
149. Basu, A.; Sanchez, K.; Leyva, M.J.; Wu, M.; Betts, N.M.; Aston, C.E.; Lyons, T.J. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J. Am. Coll. Nutr. 2010, 29, 31-40. [CrossRef]
150. Brown, A.L.; Lane, J.; Coverly, J.; Stocks, J.; Jackson, S.; Stephen, A.; Bluck, L.; Coward, A.; Hendrickx, H. Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: Randomized controlled trial. Br. J. Nutr. 2009, 101, 886-894. [CrossRef]
151. Matsuyama, T.; Tanaka, Y.; Kamimaki, I.; Nagao, T.; Tokimitsu, I. Catechin safely improved higher levels of fatness, blood pressure, and cholesterol in children. Obesity 2008, 16, 1338-1348. [CrossRef]